New lupus drug saphnelo tracked for Long-Term safety in 1,600+ patients
NCT ID NCT05141201
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking the long-term safety and effectiveness of the drug Saphnelo (anifrolumab) in over 1,600 people with systemic lupus erythematosus who haven't responded well to current treatments. Researchers are monitoring for side effects like serious infections, shingles, and allergic reactions. The goal is to see how well the drug works in real-world use over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Anifrolumab (Saphnelo)
What this could lead to
If successful, this study could confirm that anifrolumab is a safe and effective long-term option for controlling lupus in people who haven't responded to other treatments.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Risks include serious infections, shingles, and allergic reactions, as noted in the study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Aichi, Japan
-
Research Site
Akita, Japan
-
Research Site
Aomori, Japan
-
Research Site
Chiba, Japan
-
Research Site
Ehime, Japan
-
Research Site
Fukui, Japan
-
Research Site
Fukuoka, Japan
-
Research Site
Fukushima, Japan
-
Research Site
Gifu, Japan
-
Research Site
Gunma, Japan
-
Research Site
Hiroshima, Japan
-
Research Site
Hokkaido, Japan
-
Research Site
Hyōgo, Japan
-
Research Site
Ibaraki, Japan
-
Research Site
Ishikawa, Japan
-
Research Site
Kagawa, Japan
-
Research Site
Kagoshima, Japan
-
Research Site
Kanagawa, Japan
-
Research Site
Kochi, Japan
-
Research Site
Kumamoto, Japan
-
Research Site
Kyoto, Japan
-
Research Site
Mie, Japan
-
Research Site
Miyagi, Japan
-
Research Site
Miyazaki, Japan
-
Research Site
Nagano, Japan
-
Research Site
Nagasaki, Japan
-
Research Site
Nara, Japan
-
Research Site
Niigata, Japan
-
Research Site
Numakunai, Japan
-
Research Site
Okayama, Japan
-
Research Site
Okinawa, Japan
-
Research Site
Osaka, Japan
-
Research Site
Ōita, Japan
-
Research Site
Saga, Japan
-
Research Site
Saitama, Japan
-
Research Site
Shiga, Japan
-
Research Site
Shimane, Japan
-
Research Site
Shizuoka, Japan
-
Research Site
Tochigi, Japan
-
Research Site
Tokushima, Japan
-
Research Site
Tokyo, Japan
-
Research Site
Tottori, Japan
-
Research Site
Toyama, Japan
-
Research Site
Wakayama, Japan
-
Research Site
Yamagata, Japan
-
Research Site
Yamaguchi, Japan
-
Research Site
Yamanashi, Japan